ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT03602560 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: seladelpar 5-10 mg
DRUG: seladelpar 10 mg
DRUG: Placebo

Sponsor

Gilead Sciences